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Abstract  
 
Objective: To determine if functional imaging using 
11
C-methionine positron emission tomography, 
co-registered with 3D gradient echo MRI (Met-PET/MRI), can identify sites of residual active tumour 
in treated acromegaly, and discriminate these from post-treatment change, to allow further targeted 
treatment.  
  
Design/Methods: Twenty-six patients with persistent acromegaly following previous treatment, in 
whom MRI appearances were considered indeterminate, were referred to our centre for further 
evaluation over a 4.5-year period. Met-PET/MRI was performed in each case and findings were used 
to inform decision-making regarding adjunctive therapy. Four patients with clinical and biochemical 
remission post-transsphenoidal surgery (TSS), but in whom residual tumour was suspected on 
postoperative MRI, were also studied. 
  
Results: Met-PET/MRI demonstrated tracer uptake only within the normal gland in the four patients 
who had achieved complete remission following primary surgery. In contrast, in 26 patients with 
active acromegaly, Met-PET/MRI localised sites of abnormal tracer uptake in all but one case. Based 
on these findings, fourteen subjects underwent endoscopic TSS, leading to a marked improvement in 
(n=7), or complete resolution of (n=7), residual acromegaly. One patient received stereotactic 
radiosurgery and two patients with cavernous sinus invasion were treated with image-guided 
fractionated radiotherapy, with good disease control. Three subjects await further intervention. Five 
patients chose to receive adjunctive medical therapy. Only one patient developed additional pituitary 
deficits following Met-PET/MRI-guided TSS. 
  
Conclusions: In patients with persistent acromegaly following primary therapy, Met-PET/MRI can 
help identify the site(s) of residual pituitary adenoma when MRI appearances are inconclusive, and 
direct further targeted intervention (surgery or radiotherapy).  
 3 
Introduction 
Transsphenoidal surgery (TSS) remains the treatment of choice for functioning pituitary tumours 
causing acromegaly, Cushing’s disease and central hyperthyroidism (thyrotropinoma), and in patients 
with prolactinoma who are intolerant of medical therapy. However, even in the hands of experienced 
surgeons, persistent/recurrent disease requiring additional therapy (repeat surgery, radiotherapy or 
long-term medical treatment) is not uncommon, and in the case of acromegaly may be required in up 
to 50% of macroadenomas (1). Postoperative decision-making in these patients is guided by several 
factors, including clinical and biochemical assessment of endocrine status and the identification of 
residual tumour on follow-up scanning. However, standard pituitary imaging [magnetic resonance 
imaging (MRI) or, less commonly, computerised tomography (CT)] does not always reliably 
distinguish between residual tumour, post-surgical change and normal pituitary tissue (2, 3). In this 
context, the likelihood that the patient will be offered further treatment with targeted therapies such as 
repeat TSS or stereotactic radiosurgery is diminished. Although conventional fractionated 
radiotherapy is effective in controlling residual endocrine hyperfunction and preventing tumour 
growth, it carries an increased risk of hypopituitarism (4). In addition, potential links to second tumour 
growth (e.g. meningioma) and premature cerebrovascular disease have also been suggested (5), 
although recent studies have shown no additional excess beyond that observed in patients undergoing 
surgery alone (6, 7). 
 
More reliable techniques for discriminating between residual functioning tumour, post-treatment 
change and the normal pituitary gland could therefore help identify those patients with persisting 
acromegaly who are most likely to benefit from repeat TSS or targeted radiotherapy. A role for 
functional imaging in the post-operative management of pituitary tumours has been proposed 
previously, but is not currently in routine clinical use (2, 3, 8, 9). 
18
F-fluorodeoxyglucose (FDG), the 
positron emission tomography (PET) tracer most commonly employed in oncology, has been used 
successfully to locate microadenomas or residual tumour following surgery in some patients but, 
importantly, it lacks sensitivity and its utility is also limited by high uptake into surrounding normal 
brain tissue (8, 9). In contrast, 
11
C-methionine exhibits a more favourable pituitary to brain uptake 
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ratio, and several studies have demonstrated its ability to identify residual pituitary adenoma (2, 3, 9, 
11). However, a key limitation in many of the early studies was the restricted anatomical resolution 
offered by PET or PET-CT. This presents a particular challenge when trying to accurately localise 
small (sub-centimeter) lesions, which may not be readily differentiated from uptake into adjacent 
normal pituitary tissue (12). The absence of readily-available PET-MRI has prompted some workers to 
assess the utility of merging (co-registering) PET-CT and MRI images (from this point onward 
referred to as Met-PET/MRI) to provide enhanced anatomical definition at sites of 
11
C-methionine 
tracer uptake (9, 10). However, to date little data correlating imaging findings with subsequent 
treatment decisions and clinical outcomes has been reported (9, 10).  
 
Here, we report our findings in 30 consecutive patients with acromegaly referred to our service for 
further evaluation because of indeterminate post-treatment MRI appearances, and describe how 
treatment decisions were informed by the findings on Met-PET/MRI.  
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Subjects and Methods 
 
Patients 
Between June 2011 and December 2015, 30 patients [16 women, 14 men; mean age 48 yr (range 24-
75 yr)] were referred to our university teaching hospital pituitary service for further evaluation of 
suspected or confirmed residual active acromegaly following primary therapy [TSS alone in 23 
patients; TSS with adjunctive fractionated radiotherapy (RT) in three patients; TSS with adjunctive RT 
and stereotactic radiosurgery (SRS) in one patient; and primary medical therapy in three patients 
(lanreotide Autogel

, n=1; cabergoline, n=1; pegvisomant, n=1)] (Table 1). In all cases of active 
disease, patients exhibited typical clinical features, with elevated insulin-like growth factor 1 (IGF-1, 
above the age and sex-matched reference range), and failure to suppress serum growth hormone (GH) 
to <0.4 mcg/L after a 75 g oral glucose load, and/or GH levels >2.5 mcg/L (either random 
measurement or mean of five samples drawn at 30-60 minute intervals) (13). Post-treatment imaging 
had been deemed indeterminate following review by a specialist pituitary multidisciplinary team 
(MDT) in the referring centre. For patients receiving adjunctive medical therapy at the point of 
referral, we advised discontinuation of depot somatostatin analogue (SSA) therapy for a minimum of 
12 weeks, and dopamine agonist therapy for 4 weeks, prior to Met-PET/MRI. 
 
Biochemical measurements 
All analytes were measured by a Clinical Pathology Accreditation Limited laboratory (CPA, 
Middlesex, UK) with relevant internal and external quality assurance as defined by the CPA. Serum 
GH concentration was measured using a solid phase two-site time-resolved fluorometric assay 
(DELFIA
®
, PerkinElmer Life and Analytical Sciences Inc., Waltham, Massachusetts, USA) calibrated 
to IS 98/574 (analytical sensitivity 0.01 ng/mL; interassay coefficient of variation <5 % across the 
range 0.025–25 ng/mL). Serum samples giving GH higher than this were diluted with zero standard as 
provided by the manufacturer. Serum IGF-1 was measured using a solid-phase enzyme labelled 
chemiluminescent immunometric assay (Siemens Immulite2000
®
 – Siemens Medical Solutions 
Diagnostics Ltd., Llanberis, Gwynedd, UK) calibrated to IS 87/518 (analytical sensitivity 20 ng/mL; 
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interassay coefficient of variation <10 % across the range 25–1600 ng/mL), and results are shown as  
upper limit of normal (ULN). 
 
Clinical care 
All patients were managed in accordance with local and international clinical guidelines (14) and all 
patients provided informed consent for Met-PET and 3D gradient echo MRI. The decision to offer 
further treatment was undertaken on a case-by-case basis following discussion by a specialist pituitary 
multidisciplinary team (MDT) comprising pituitary neurosurgeon(s), endocrinologist(s), 
otolaryngologist(s), radiation oncologist(s), neuropathologist(s) and neuroradiologist(s), who had full 
access to the Met-PET/MRI scans to aid decision-making. Further surgery or radiotherapy was 
undertaken either at our centre or the referring hospital. The study received Institutional approval. 
 
Pathological examination 
Surgical specimens were fixed in 10% neutral buffered formalin and embedded in paraffin. 
Histopathological confirmation of the presence of a somatotroph tumour was verified by the findings 
of typical microscopic appearances for a pituitary adenoma with positive immunohistochemical (IHC) 
staining for growth hormone.  
 
Synthesis of 
11
C-methionine 
The PET tracer, L-[methyl-
11
C]-methionine, was synthesised in compliance with good manufacturing 
practice using a captive solvent in loop methylation method without preparative HPLC, adapted from 
methods published previously (15-17). Briefly, [
11
C]CO2 was produced using a PETtrace cyclotron 
(GE Medical Systems) via the 
14N(p,α)11C reaction before conversion to [11C]MeI in the MeI 
MicroLab (GE Medical Systems). This was then transferred to the HPLC loop of a modified 
TracerLabFXC (GE Medical Systems) synthesiser containing an L-homocysteine precursor solution 
(0.5M aqueous NaOH solution in ethanol). 
11
C-methionine was produced in yields up to 15GBq with a 
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radiochemical purity of >96% and specific activity between 32.2 and 1564 GBq/µmol (average 205.5 
GBq/µmol). 
 
Met-PET imaging 
All scans were acquired on a GE Discovery 690 PET-CT scanner (GE Medical Systems, Milwaukee, 
WI, USA). The study was performed 20 min after intravenous administration of 300-400 MBq of L- 
[methyl-
11
C]- methionine. A low dose CT (140 kV, 220 mA, 0.5s rotation, 0.984 mm pitch) was 
acquired for attenuation correction followed by a single bed position PET study of the head. Time-of-
Flight (ToF) PET data were acquired for a total acquisition time of 20 min. PET images were 
reconstructed with CT attenuation correction using fully 3D iterative reconstruction algorithms (3 
iterations, 24 subsets, 2 mm Gaussian post-filter) incorporating ToF & resolution recovery software 
(VUE Point FX and Sharp IR) to a 3.27 mm slice thickness.  The CT images were reconstructed at 
1.25 mm slice thickness. Met-PET studies were reviewed by nuclear medicine physicians with 
expertise in PET-CT on the Xeleris workstation (GE Healthcare).  
 
Standard and 3D gradient echo MRI 
Imaging was performed on a 1.5T superconducting unit (GE Signa

, Milwaukee, USA) using a 
circularly-polarised head coil. For standard clinical MRI, coronal T1-weighted spin echo images were 
obtained before and after intravenous injection of 0.1 mmol/kg gadopentetate dimeglumine. 
Subsequently, a spoiled gradient recalled acquisition (SPGR) sequence was also performed to optimise 
co-registration with the Met-PET dataset. In brief, sagittal T1-weighted fast spoiled gradient echo 
images (TR 11.5 ms, TE 4.2 ms, slice thickness 1 mm, 0 mm gap, 256  256 matrix) of the whole 
head were obtained. The absence or presence of cavernous sinus invasion was defined according to 
Knosp criteria (18). MRI scans were reviewed by neuroradiologists and members of the pituitary 
MDT both at the local/referring hospitals and in Cambridge. 
 
Co-registration of Met-PET and MRI 
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Met-PET and MRI images were co-registered using ProSoma version 3.3, Build 252 software 
(MedCom GmbH). ProSoma is a virtual simulation package used primarily in radiotherapy. It allows 
multiple datasets to be loaded simultaneously and co-registered with each other using a mutual 
information based automatic registration algorithm. For the purposes of this work the SPGR MRI 
sequence was selected as the primary dataset. The CT dataset acquired as part of the Met-PET imaging 
was then registered to the MRI and the resulting registration parameters applied to the PET data to 
achieve a Met-PET/MRI registration. 
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Results 
 
Patients with indeterminate MRI appearances but complete remission of acromegaly  
Four patients (cases 14) were in complete remission (clinically and biochemically) following primary 
TSS (Table 1). However, in each of these patients the post-operative MRI (performed at 3-4 months 
after surgery) showed suspected residual disease at the site of the original tumour. Two 
neuroradiologists were unable to distinguish between possible residual tumour and post-operative 
change in each of these patients. In contrast, Met-PET/MRI showed only tracer accumulation 
corresponding to the normal pituitary gland, with no uptake at sites of suspected residual tumour (Figs 
1 and 2).  
 
Patients with indeterminate MRI appearances and persistent acromegaly 
Twenty-six patients with acromegaly had active disease (cases 5–30) despite previous treatment(s) 
(Table 1). The majority of patients had undergone single TSS (n=18). Two patients had undergone 
repeat TSS (cases 15 & 16), one of whom (case 16) had also received post-operative RT. Two patients 
(cases 26 & 29) had undergone single TSS followed by RT. Another patient (case 30) had undergone 
TSS, conventional RT and stereotactic radiosurgery sequentially, with continuing poor control 
necessitating maximum dose of pegvisomant. Three further patients (cases 17, 18, 19) had never been 
offered surgery due to the absence of a clear surgical target on MRI, which showed a large, partially 
empty sella (Table 1). Several patients were receiving adjunctive medical therapy (depot SSA in 17; 
cabergoline in one), which was discontinued prior to Met-PET/MRI (see section: Subjects and 
methods). 
 
In 25 cases (96%), Met-PET/MRI revealed tracer uptake at sites that were clearly visualised to be 
separate from the normal pituitary gland (Table 1 and Figs. 3-7). Some, but not all of these sites had 
been independently identified as suspicious for residual adenoma on MRI, but with the caveat that the 
reporting radiologists (and referring pituitary multidisciplinary teams) were unable to definitively 
distinguish them from post-treatment changes. In one patient (case 8), Met-PET/MRI did not show any 
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tracer uptake at a site of suspected recurrence (5mm area adjacent to the left cavernous sinus). 
However, it transpired that this patient had received a 90mg depot injection of Lanreotide Autogel
®
 
(ATG) just five weeks prior to being scanned, which may have suppressed 
11
C-Methionine uptake by 
the tumour. 
 
Based on the Met-PET/MRI findings, 14 patients were referred for first or repeat TSS (Table 1). In all 
14 cases tumour was localised intra-operatively at the sites previously identified as abnormal on Met-
PET/MRI, and histological analysis confirmed GH-secreting pituitary adenoma in all but two patients; 
both of the latter, however, remain in full remission at one and two years’ follow up respectively off 
all treatment (case 7 and case 19). Post-operative endocrine testing (6-12 weeks after TSS and a 
minimum of 12 weeks after discontinuing medical therapy) showed a marked improvement in disease 
control in seven patients (with IGF-1 <2.0 ULN in six subjects), and complete biochemical remission 
in the other seven cases (Table 1). Reassuringly, only one patient developed new pituitary hormone 
deficits following Met-PET/MRI guided surgery (LH, FSH, TSH in subject 5). The only other patient 
to acquire a new hormone deficit (ACTH) following TSS was case 8 (the single subject with a 
negative Met-PET/MRI) (Table 1). 
 
One patient underwent stereotactic radiosurgery (case 28) and achieved biochemical control at one 
year post-treatment; he is now being considered for withdrawal of medical therapy. Two patients 
(cases 21 & 22), in whom Met-PET/MRI demonstrated clear cavernous sinus invasion, received 
adjunctive fractionated RT with subsequent normalisation of GH and IGF-1 off all medical therapy by 
24 and 48 months respectively. Five patients (cases 23-27) were treated with SSA after rejecting 
alternative treatment options (Table 1). Three patients are currently awaiting further surgery or 
stereotactic radiosurgery.  
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Discussion 
In an important subgroup of patients with acromegaly, post-treatment MRI (and/or CT) is unable to 
reliably identify the site(s) of residual/recurrent pituitary adenoma or distinguish suspected adenoma 
from post-therapy change (e.g. sella remodelling due to scar tissue). In this setting, adjunctive medical 
therapy (e.g. SSA, dopamine agonist, pegvisomant) or fractionated radiotherapy are often preferred 
because of the lack of a clear target for (repeat) TSS or stereotactic radiosurgery (SRS). While good 
disease control can be achieved in the majority of patients with medical therapy and/or conventional 
radiotherapy, they are associated with significant long-term cost (e.g. SSA, pegvisomant) or potential 
adverse effects (e.g. hypopituitarism following radiotherapy). Here, we have shown in the largest 
cohort of acromegaly patients studied to date that Met-PET/MRI can provide additional data (Figs. 
37) to help inform management in such cases, and may facilitate further targeted treatment with a 
high probability of achieving a significant improvement in, or complete, disease control. Met-
PET/MRI can also exclude suspected residual tumour following successful surgery (Figs. 1 and 2). 
 
A potential role for functional imaging with PET in pituitary disease has previously been suggested by 
several groups (2, 3, 8-11, 19). Proposed indications include detection of microadenomas where MRI 
is either negative or inconclusive (e.g. in up to 40% of Cushing’s disease) (10, 19), discrimination 
between post-operative changes and residual active adenoma (in non-functioning and functioning 
tumours) (3, 9, 11), and to evaluate the effects of treatment (e.g. radiotherapy, medical therapy) (2, 8, 
20). Although FDG-PET has shown utility in some patients, its limited sensitivity (especially for 
detecting microadenomas) coupled with high background uptake by normal brain have prevented its 
adoption into routine clinical practice. In contrast, 
11
C-methionine shows considerably lower brain 
uptake (producing a much more favourable target:background ratio), with several studies also 
reporting increased sensitivity compared with FDG-PET (10, 11). Estimation of tumour metabolism 
through measurement of the maximum standard(ised) uptake value (SUVmax), and comparison to 
background cerebellar uptake, may help to confirm non-physiological sella uptake (a ratio >2 has been 
proposed as exceeding that seen in normal pituitary tissue) (2), although ratios <2 may be seen in some 
tumour subtypes (e.g. corticotroph microadenomas) or when there is low volume residual disease, 
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making this an unreliable means of confirming or refuting the presence of residual functioning tumour 
(9, 10). 
 
Early PET studies were limited by a lack of spatial resolution, and even modern PET-CT cannot match 
the anatomical definition offered by MRI (21). In pituitary disease this presents significant challenges, 
for example when trying to locate a small (<5mm) microadenoma within an otherwise normal gland, 
or determine whether laterally-situated tumour is simply abutting or invading (and therefore 
potentially unresectable) the adjacent cavernous sinus (11). In recognition of this, a small number of 
studies have been performed in which PET-CT images have been co-registered with contemporaneous 
fine slice MRI (thereby combining the sensitivity of PET-CT with the anatomical resolution of MRI), 
with initial reports suggesting significant benefits for tumour localisation (9, 10, 19). If confirmed, 
these findings provide strong support for future studies using PET-MR. 
 
To date, only a relatively small number of patients with acromegaly have been included in studies of 
Met-PET, but with generally positive findings. For example, Tang and colleagues studied four patients 
with acromegaly in a group of 33 patients with biochemical or radiological evidence of pituitary 
adenoma recurrence following surgery (3). In 14 of these patients (three of whom had persisting 
acromegaly), Met-PET detected residual tumour which was not visible on MRI. This information was 
used to guide stereotactic radiosurgery in 9 patients, including one of those with acromegaly (3). More 
recently, Rodriguez-Barcelo et al studied 17 patients with newly diagnosed or surgically treated 
acromegaly using co-registered PET-CT and MRI. They reported 86% sensitivity and 86% specificity 
for detecting recurrence following surgery. However, importantly only one patient proceeded to PET 
guided treatment (SRS), and no outcome data were provided to confirm the accuracy of the imaging 
findings (9). Feng and colleagues, comparing FDG-PET and Met-PET in 43 patients with secretory 
pituitary adenomas, including 16 patients with acromegaly, concluded that while FDG-PET showed 
high specificity, Met-PET demonstrated greater sensitivity (11). Interestingly, all patients in their 
cohort had visible tumours on MRI. 
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Our study significantly extends these earlier findings, reporting the outcomes of Met-PET/MRI in 30 
UK patients in whom specialist pituitary multidisciplinary teams had concluded that post-treatment 
MRI appearances were indeterminate. We therefore deliberately focused on cases in whom 
management decisions could benefit from additional information regarding the location of residual 
tumour [i.e. those who might be considered for further surgery, SRS or focused fractionated 
radiotherapy (i.e. confined to site of suspected tumour remnant only)]. We have also provided detailed 
surgical, pathological and post-operative data for each case, thus correlating Met-PET/MRI findings 
with key clinical outcomes.  
 
Importantly, in four patients with suspected residual tumour on post-operative MRI, but no clinical or 
biochemical evidence of active disease, Met-PET/MRI demonstrated no abnormal tracer uptake (Figs. 
1 and 2). Such findings may explain the apparent discrepancies noted by other workers in post-surgical 
acromegaly (22). In contrast, in 25 of 26 patients with persistent disease following primary therapy, 
Met-PET/MRI identified one or more foci of abnormal tracer uptake either confirming suspicious 
areas seen on MRI or revealing previously unsuspected sites of residual disease (Table 1) (Figs. 3–7). 
In all 25 patients the findings of Met-PET/MRI were used to inform decision-making by a specialist 
pituitary multidisciplinary team with respect to adjunctive therapy. In 15 patients repeat (n=12) or first 
(n=3) TSS were advised, and in the 14 patients operated to date, all had intraoperative confirmation of 
residual tumour at the sites suspected on Met-PET/MRI. Although two patients had negative 
histology, both remain in remission after TSS. All patients experienced a significant improvement in 
disease control, with six achieving IGF-1 <2.0ULN and seven full biochemical remission. 
Interestingly, in the three patients considered to have a predominantly empty sella on initial MRI, such 
that surgery was not considered advisable, Met-PET/MRI identified clear foci of microscopic disease 
(subsequently confirmed at surgery to be adherent to a thin layer of residual normal pituitary tissue) 
(Fig. 6). Two of these patients were able to discontinue medical therapy completely following surgery, 
while the third had an 85% reduction in GH levels. For other patients, Met-PET/MRI confirmed the 
suspicion of significant parasellar disease and led to recommendations to continue adjunctive medical 
therapy or consider fractionated RT or SRS (Table 1).  
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In one patient (case 29) Met-PET/MRI offered an explanation for the failure of previous SRS to 
achieve complete disease control, identifying foci of residual functioning adenoma that were outside 
the SRS treatment field (Fig. 7).  
 
We believe our findings therefore provide additional evidence to support a role for Met-PET/MRI in 
selected cases of acromegaly where there is evidence of residual disease activity following primary 
therapy, but in whom post-treatment MRI is inconclusive. Specifically, we have identified three 
potential indications: 
i. To distinguish between residual functioning tumour and post-treatment remodelling  
ii. To delineate sites of residual adenoma that are potentially amenable to (further) surgery or targeted 
radiotherapy in patients with persistent disease following primary therapy, but indeterminate MRI 
findings 
iii. To confirm sites of residual functioning tumour following failed RT or SRS 
 
Met-PET/MRI has one major drawback - due to the short half-life of 
11
C-methionine (20 min), 
scanning can only be performed in PET centres with an adjacent cyclotron. This inevitably means that 
some patients will need to travel significant distances to be imaged. However, it can be argued that 
concentrating expertise in only a small number of centres is also potentially desirable, especially for a 
technique that is only likely to find use in a subgroup of patients. In addition, our observations in case 
8 are consistent with previous reports that medical treatment which specifically suppresses hormone 
synthesis may result in a false negative scan. Accordingly, we would agree with previous 
recommendations to discontinue depot SSA therapy 12 weeks, and dopamine agonist therapy 4 weeks, 
prior to functional imaging with 
11
C-methionine PET.  
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Conclusions 
Met-PET/MRI represents an important opportunity for personalising management (23) in selected 
patients with acromegaly. We have shown that accurate localisation of residual tumour can facilitate 
targeted therapy to increase the rate of clinical and biochemical remission, while preserving normal 
pituitary function, and potentially sparing expensive long-term medical treatment or the adverse 
effects of RT.  
 
 
 
Declaration of interest 
The authors declare that there is no conflict of interest that could be perceived as prejudicing the 
impartiality of the research reported. 
 
Funding 
This research did not receive any specific grant from any funding agency in the public, commercial or 
not-for-profit sector. 
 
Acknowledgements 
The authors thank clinicians who have referred patients to our centre for further investigation. The 
authors also thank the WBIC Radiopharmaceutical Unit team. OK, ASP, NB, JDP and MG are 
supported by the NIHR Cambridge Biomedical Research Centre. JDP has received support by an 
NIHR Senior Investigator award and NIHR brain injury HTC.  
 
  
 16 
References 
 
1. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with 
acromegaly using current criteria of biochemical ‘cure’. European Journal of Endocrinology. 
2005 152 379–87. 
2. Bergström M, Muhr C, Lundberg PO, Långström B. PET as a tool in the clinical evaluation of 
pituitary adenomas. Journal of Nuclear Medicine 1991 32 610–5. 
3. Tang BN, Levivier M, Heureux M, Wikler D, Massager N, Devriendt D, David P, Dumarey N, 
Corvilain B, Goldman S. 11C-methionine PET for the diagnosis and management of recurrent 
pituitary adenomas. European Journal of Nuclear Medicine and Molecular Imaging 2006 33 
169–78. 
4. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism 
following external radiotherapy for pituitary tumours in adults. Quarterly Journal of Medicine 
1989 70 145–60. 
5. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumor after 
conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 
years. Journal of Clinical Endocrinology and Metabolism 2005  90 800–4. 
6.  Sattler MG, Vroomen PC, Sluiter WJ, Schers HJ, van den Berg G, Langendijk JA, 
Wolffenbuttel BH, van den Bergh AC, van Beek AP. The incidence of second tumours and 
mortality in pituitary adenoma patients treated with postoperative radiotherapy versus surgery 
alone. Radiotherapy and Oncology 2012 104 125–30. 
7.  Sattler MG, Vroomen PC, Sluiter WJ, Schers HJ, van den Berg G, Langendijk JA, 
Wolffenbuttel BH, van den Bergh AC, van Beek AP. Incidence, causative mechanisms, and 
anatomic localization of stroke in pituitary adenoma patients treated with postoperative 
radiation therapy versus surgery alone. International Journal of Radation Oncology, Biology, 
Physics 2013 87 53–9.  
8. Muhr C. Positron emission tomography in acromegaly and other pituitary adenoma patients. 
Neuroendocrinology 2006 83 205–10. 
 17 
9. Rodriguez-Barcelo S, Gutierrez-Cardo A, Dominguez-Paez M, Medina-Imbroda J, Romero-
Moreno L, Arraez-Sanchez M.Clinical usefulness of coregistered 11C-methionine positron 
emission tomography/3-T magnetic resonance imaging at the follow-up of acromegaly. World 
Neurosurgery 2014 82 468–73. 
10. Ikeda H, Abe T, Watanabe K. Usefulness of composite methionine-positron emission 
tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of 
early-stage Cushing adenoma. Journal of Neurosurgery 2010 112 750–5. 
11. Feng Z, He D, Mao Z, Wang Z, Zhu Y, Zhang X, Wang H. Utility of 11C-Methionine and 18F-
FDG PET/CT in Patients With Functioning Pituitary Adenomas. Clinical Nuclear Medicine 
2016 41 e130–4. 
12. Tomura N, Saginoya T, Mizuno Y, Goto H. Accumulation of 11C-methionine in the normal 
pituitary gland on 11C-methionine PET. Acta Radiologica 2016 57 325-332. 
13. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, 
Ghigo E, Ho K, Melmed S; Acromegaly Consensus Group. A consensus on criteria for cure of 
acromegaly. Journal of Clinical Endocrinology and Metabolism 2010 95 3141–8. 
14. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA; Endocrine 
Society. Acromegaly: an endocrine society clinical practice guideline. Journal of Clinical 
Endocrinology and Metabolism 2014 99 3933–51. 
15. Pascali C. Bogni A, Iwata R, Bombardieri E. High efficiency preparation of L-[S-methyl-
11C]methionine by on-column [11C]methylation on C18 Sep-Pak. Journal of Labelled 
Compounds and Radiopharmaceuticals 1999 42 715–724. 
16. Mitterhauser M, Wadsak W, Krcal A, Kletter K. New aspects on the preparation of 
[11C]Methionine--a simple and fast online approach without preparative HPLC. Applied 
Radiation and Isotopes 2005 62 441–5. 
17. Gómez V, Gispert JD, Amador V, Llop J. New method for routine production of L-[methyl-
11C]methionine:in loop synthesis. Journal of Labelled Compounds and Radiopharmaceuticals 
2008 51 83–86. 
18. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus 
 18 
space: a magnetic resonance imaging classification compared with surgical findings. 
Neurosurgery 1993 33 610–7; discussion 617–8. 
19. Koulouri O, Steuwe A, Gillett D, Hoole AC, Powlson AS, Donnelly NA, Burnet NG, Antoun 
NM, Cheow H, Mannion RJ, Pickard JD, Gurnell M. A role for 11C-methionine PET imaging 
in ACTH-dependent Cushing’s syndrome. European Journal of Endocrinology 2015 173 
M107–20. 
20. van den Bergh AC, Pruim J, Links TP, van der Vliet AM, Sluiter W, Wolffenbuttel BH, 
Langendijk JA, Hoving EW, Dullaart RP. Tyrosine positron emission tomography and protein 
synthesis rate in pituitary adenoma: Different effects of surgery and radiation therapy. 
Radiotheapy and  Oncology 2011 98 213–216. 
21. Chittiboina P, Montgomery BK, Millo C, Herscovitch P, Lonser RR. High-resolution(18)F-
fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for 
pituitary adenoma detection in Cushing disease. Journal of Neurosurgery 2015 122 791–7. 
22. Jane JA, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, Marshall JC, Laws 
ER Jr, Vance ML., Endoscopic transsphenoidal surgery for acromegaly: remission using 
modern criteria, complications, and predictors of outcome. Journal of Clinical Endocrinology 
and Metabolism 2011 96 2732–40. 
23. Melmed, S. Pituitary Medicine From Discovery to Patient-Focused Outcomes. Journal of 
Clinical Endocrinology and Metabolism 2016 101 769–77. 
 
 
 
 
 
 
 
 
 
 19 
Figure legends 
 
Figure 1: Case 1 (acromegaly in remission post-TSS). Post-operative MRI suggests a significant 
right-sided tumour remnant (white arrows), with normal gland (contrast enhanced, yellow arrow) 
displaced superiorly to the left; but Met-PET/MRI demonstrates tracer uptake only at the site of the 
normal gland, and confirms no residual functioning tumour at the site of the suspected remnant 
reported on routine clinical MRI. 
Key: Met-PET-CT, 
11
C-methionine PET-CT; Met-PET/MRI, co-registered 
11
C-methionine PET-CT 
and MRI; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1-weighted; TSS, transsphenoidal 
surgery.  
 
Figure 2: Case 2 (acromegaly in remission post-TSS). Post-operative MRI suggests a possible 
tumour remnant (white arrows), inferior to the normal gland (contrast enhanced, yellow arrows). Met-
PET/MRI demonstrates tracer uptake only at the site of the normal gland, and confirms no residual 
functioning tumour at the site of the suspected remnant 
Key: Met-PET-CT, 
11
C-methionine PET-CT; Met-PET/MRI, coregistered 
11
C-methionine PET-CT 
and MRI; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1-weighted; TSS, transsphenoidal 
surgery.  
 
Figure 3: Case 5 (persistent active acromegaly post-first TSS). Post-operative MRI suggests a 
possible sella remnant [white arrows inferior to normal gland (yellow arrows)]; Met-PET/MRI reveals 
tracer uptake (white arrows) in the sella and adjacent to the left internal carotid artery where the 
greatest intensity is observed (Met-PET axial image, white arrow). 
Key: Met-PET-CT, 
11
C-methionine PET-CT; Met-PET/MRI, co-registered 
11
C-methionine PET-CT 
and MRI; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1-weighted; TSS, transsphenoidal 
surgery.  
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Figure 4: Case 11 (persistent active acromegaly post-first TSS). Post-operative MRI shows a thin 
rind of enhancing tissue lining the floor of the sella (yellow area) with a hypointense area adjacent to / 
extending into the left cavernous sinus (white arrows). Met-PET/MRI reveals tracer uptake 
predominantly in the left side of the sella adjacent to the cavernous sinus (white arrows), with greatest 
intensity seen at the posterior aspect (Met-PET axial image, white arrow).  
Key: Met-PET-CT, 
11
C-methionine PET-CT; Met-PET/MRI, coregistered 11C-methionine PET-CT 
and MRI; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1-weighted; TSS, transsphenoidal 
surgery.   
 
Figure 5: Case 16 (persistent active acromegaly despite TSS2 and fractionated RT). MRI shows 
a suspicious area on the right side of the sella with possible cavernous sinus extension (white arrows). 
Met-PET/MRI confirms tracer uptake in this area without evidence of cavernous sinus invasion. The 
position of presumed residual normal pituitary tissue is also shown (yellow arrow). 
Key: Met-PET-CT, 
11
C-methionine PET-CT; Met-PET/MRI, co-registered 
11
C-methionine PET-CT 
and MRI; RT, fractionated radiotherapy; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1-
weighted; TSS, transsphenoidal surgery.  
 
Figure 6: Case 17 (persistent active acromegaly despite maximum dose pegvisomant). MRI 
shows an enlarged, partially empty sella with no convincing ‘surgical target’. Met-PET reveals foci of 
increased tracer uptake throughout the sella (white arrows) with maximum left-sided intensity. Met-
PET/MRI localizes the sites of increased tracer uptake in the pituitary fossa with maximum intensity 
on the left.  
Key: Met-PET, 
11
C-methionine PET; Met-PET/MRI, co-registered 
11
C-methionine PET-CT and MRI; 
SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1-weighted; TSS, transsphenoidal surgery.  
 
Figure 7: Case 29 (persistent active acromegaly post-first TSS and RT). Post-operative MRI 
shows a thin rind of poorly enhancing tissue within the floor of the sella [white arrow, coronal (1) 
image] and a possible second discrete hypointense area adjacent to the left cavernous sinus [white 
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arrow, coronal (2) image]. The pituitary stalk is displaced to the right (yellow arrow). Met-PET/MRI 
reveals tracer uptake at both sites of suspected residual tumour (white arrows), with greatest intensity 
seen in the tissue lining the floor of the sella centrally (Met-PET axial image, dashed white arrow).  
Key: Met-PET-CT, 
11
C-methionine PET-CT; Met-PET/MRI, co-registered 
11
C-methionine PET-CT 
and MRI; RT, fractionated radiotherapy; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1-
weighted; TSS, transsphenoidal surgery. 
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